Selpercatinib(Retevmo)

On May 8, 2020, Selpercatinib, as a prescription drug targeting the RET protein, was the first to be approved by the U.S. Food and Drug Administration (FDA). Use only as directed by a physician.

Target of Action

RET protein

Dosage and Administration

The dosage of selpercatinib should be adjusted according to the patient’s actual condition. For specific details, please consult a doctor and strictly follow medical advice.

Recommended Reading: Dosage and Administration of Selpercatinib (Retevmo)

Side Effects

Common side effects: Diarrhea, fatigue, dry mouth, etc.

Serious side effects: Liver problems, lung problems, hypertension, etc.

Reference Article: Side Effects of Selpercatinib (Retevmo)

Use in Special Populations

Pregnancy:

Your doctor will perform a pregnancy test before you start treatment with selpercatinib.

You should use effective contraception during treatment and for 1 week after the last dose of selpercatinib.

Lactation:

It is not known whether selpercatinib passes into breast milk.

Do not breastfeed during treatment with selpercatinib and for 1 week after the last dose.

Daily Precautions

1. Patients should be informed that hepatotoxicity may occur. If any signs or symptoms related to hepatotoxicity appear, contact a healthcare professional immediately.

2. Patients should be informed that blood pressure needs to be monitored regularly. If symptoms of elevated blood pressure or high measurements occur, contact a healthcare professional.

3. Patients should be informed that selpercatinib may cause QT interval prolongation. If any symptoms related to QT interval prolongation (such as syncope) occur, inform a healthcare professional.

from FDA，2024.06